On Thursday, Generac Holdings Inc. (NYSE:GNRC)’s shares declined -10.32% to $41.69.
Generac Holdings Inc. (GNRC) stated financial results for its first quarter ended March 31, 2015.
First Quarter 2015 Highlights
- Net sales were $311.8 million during the first quarter of 2015 as contrast to $342.0 million in the preceding-year first quarter.
- Residential product sales were $156.8 million during the first quarter as contrast to $164.0 million in the preceding-year quarter, primarily due to lower portable generator shipments resulting from a decline in power outage severity contrast to the preceding year.
- Commercial & Industrial (C&I) product sales were $133.8 million during the first quarter as contrast to $157.4 million in the preceding-year quarter, primarily due to a decline in shipments to telecom national account customers and, to a lesser extent, oil & gas markets.
Generac Holdings Inc. designs, manufactures, and markets power generation equipment and other engine powered products for the residential, light commercial, industrial, oil and gas, and construction markets in the United States, Canada, and internationally. It offers engines, alternators, transfer switches, and other components fueled by natural gas, liquid propane, gasoline, diesel, and bi-fuel.
Cardiovascular Systems Inc (NASDAQ:CSII)’s shares dropped -10.11% to $31.30.
Cardiovascular Systems Inc (CSII) stated financial results for its fiscal third quarter ended March 31, 2015.
The company’s third-quarter revenues raised 35 percent to $47.0 million, from $34.9 million in the third quarter of fiscal 2014. Coronary revenues grew to $7.9 million. Customer reorder revenues remained strong at 95 percent of total revenue, contrast to 96 percent a year ago. Gross profit margin remained comprising at 78 percent.
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products comprise catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee.
At the end of Thursday’s trade, Charles River Laboratories (NYSE:CRL)‘s shares dipped –9.30% to $69.16.
Charles River Laboratories (CRL) stated its results for the first quarter of 2015. For the quarter, revenue from ongoing operations was $320.4 million, an enhance of 7.0% from $299.4 million in the first quarter of 2014. Foreign currency translation reduced stated revenue growth by 5.8%. On a constant-currency basis, revenue growth of 12.8% was driven by the Discovery and Safety Assessment segment. The Early Discovery acquisitions in 2014, which comprise Argenta, BioFocus, and ChanTest, contributed 8.0% to merged first-quarter revenue growth, both on a stated basis and in constant currency.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), ended its Thursday’s trading session with -9.23% loss, and closed at $3.54.
Threshold Pharmaceuticals, Inc. (THLD) stated financial results for the first quarter 2015. Revenue for the first quarter ended March 31, 2015 was $3.7 million. The operating loss for the first quarter ended March 31, 2015 was $9.6 million. The net loss for the first quarter ended March 31, 2015 was $11.2 million, which comprised of the operating loss of $9.6 million and non-cash expense of $1.5 million related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). As of March 31, 2015, Threshold had $83.1 million in cash, cash equivalents and marketable securities, with no debt outstanding.
Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.